The Potential Benefit of Xiao-Yao-San Treatment in Patients With Insomnia
Launched by YU-CHING HSU · May 12, 2024
Trial Information
Current as of February 19, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 20- to 65-year-old patients.
- • Pittsburgh Sleep Quality Index (PSQI) scores ≥ 5.
- Exclusion Criteria:
- • Schizophrenia.
- • Narcolepsy.
- • Neurological diseases (history of stroke, neurodegenerative diseases, etc.).
- • Alcohol addiction.
- • Drug addiction.
Trial Officials
YU-CHING HSU
Principal Investigator
Tainan Hospital, Ministry of Health and Welfare
About Yu Ching Hsu
Yu-Ching Hsu is a dedicated clinical trial sponsor focused on advancing medical research and innovative therapies. With a robust commitment to improving patient outcomes, Hsu leads initiatives that prioritize safety, efficacy, and ethical standards in clinical trials. By collaborating with diverse stakeholders, including healthcare professionals and regulatory agencies, Yu-Ching Hsu aims to accelerate the development of groundbreaking treatments while ensuring compliance with industry best practices. Through meticulous oversight and a patient-centered approach, Hsu strives to contribute valuable insights to the medical community and enhance the quality of care for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tainan, , Taiwan
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0